Repare Therapeutics Inc.
RPTX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $11,620 | $250 | $0 | $0 |
| % Growth | 4,548% | – | – | – |
| Cost of Goods Sold | $0 | $0 | $1,186 | $454 |
| Gross Profit | $11,620 | $250 | -$1,186 | -$454 |
| % Margin | 100% | 100% | – | – |
| R&D Expenses | $7,502 | $14,283 | $18,949 | $24,355 |
| G&A Expenses | $4,548 | $6,029 | $0 | $0 |
| SG&A Expenses | $4,548 | $6,029 | $7,652 | $5,847 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$1,561 | -$2,282 | $0 | $0 |
| Operating Expenses | $10,489 | $18,030 | $26,601 | $30,202 |
| Operating Income | $1,131 | -$17,780 | -$27,787 | -$30,656 |
| % Margin | 9.7% | -7,112% | – | – |
| Other Income/Exp. Net | $2,272 | $1,284 | -$1,751 | $2,125 |
| Pre-Tax Income | $3,403 | -$16,496 | -$29,538 | -$28,531 |
| Tax Expense | $145 | $248 | $505 | $140 |
| Net Income | $3,258 | -$16,744 | -$30,043 | -$28,671 |
| % Margin | 28% | -6,697.6% | – | – |
| EPS | 0.08 | -0.39 | -0.71 | -0.67 |
| % Growth | 120.5% | 45.1% | -6% | – |
| EPS Diluted | 0.08 | -0.39 | -0.71 | -0.67 |
| Weighted Avg Shares Out | 42,966 | 42,922 | 42,592 | 42,411 |
| Weighted Avg Shares Out Dil | 43,052 | 42,922 | 42,592 | 42,411 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2,224 | $1,236 | $1,538 | $2,017 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $72 | $1,036 | $1,186 | $454 |
| EBITDA | $3,475 | -$19,026 | -$28,352 | -$28,077 |
| % Margin | 29.9% | -7,610.4% | – | – |